



# LANXESS - Q3 2013 Results Conference Call

Taking action in a challenging environment

Axel C. Heitmann, CEO Bernhard Duettmann, CFO




#### Safe harbor statement

The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United States.


This presentation contains certain forward-looking statements, including assumptions, opinions and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.



# Executive overview Q3 2013 Business and financial review Q3 2013 Outlook/Guidance



# Volumes start to recover, prices decrease raw-material driven




Q3 vs Q2 2013	Price	Volume	Currency	Portf.
Perf. Polymers -7%	-8%	2%	-1%	0%
Adv. Interm. +2%	-2%	5%	-1%	0%
Perf. Chemicals -3%	0%	-1%	-1%	0%
LANXESS -4%	-5%	+2%	-1%	0%

- Sequential price decreases driven by raw material price decline (e.g. butadiene US/EU contract around -40%\*)
- Volume recovery continues, indicating stabilization of business environment
- Burden from currency developments (US Dollar)

LANXESS

# Q3 2013: Notable volume increases do not compensate lower price levels





- Notable volume recovery in all segments partly on a low base in Q3 2012
- Significantly lower prices in Performance Polymers and negative currency burden quarterly performance
- Increased sales volumes mainly catered from inventories
- EBITDA burdened as highvalued inventory met current lower market prices

**LANXESS** 

6

<sup>\*</sup> ICIS: Monthly contract June vs September 2013 as well as average Q2 vs Q3 2013 development





# Q3 2013 financial overview: Results still unsatisfactory

[€ m]	Q3 2012	Q2 2013	Q3 2013	yoy in %
Sales	2,159	2,141	2,050	-5.0%
EBITDA pre except.	254	198	187	-26.4%
margin	11.8%	9.2%	9.1%	
EPS	1.10	0.11	0.13	-88.0%
EPS pre <sup>1</sup>	1.14	0.42	0.32	-72.2%
Capex <sup>2</sup>	152	159	146	-3.9%
[€ m]	31.12.2012	30.06.2013	30.09.2013	% vs FY
Net financial debt	1,483	2,018	1,822	22.9%
Net working capital	1,849	2,082	1,873	1.3%
Employees	17,177	17,494	17,502	1.9%

- Sales decline on lower pricing and negative currency, while positive volumes mitigate (yoy and sequentially)
- EBITDA burdened by lower selling prices; inventory devaluation (~€10 m) additionally digested
- Exceptional items of €21 m mainly for "Advance" weigh on Q3 EPS
- Net debt decreases sequentially mainly due to working capital reduction

Volume increase not reflected in earnings

2012 restated due to IAS 19 (revised)

<sup>1</sup> Net of exceptionals and respective tax effects

<sup>2</sup> Net of capitalized borrowing costs and projects financed by customers

**LANXESS** 

# Q3 2013: Weakness continues - countermeasures initiated

[€ m]	Q3 2	2012	Q3 2	2013	yoy in %
Sales	2,159	(100%)	2,050	(100%)	-5%
Cost of sales	-1,699	(79%)	-1,662	(81%)	-2%
Selling	-183	(8%)	-186	(9%)	2%
G&A	-80	(4%)	-76	(4%)	-5%
R&D	-49	(2%)	-43	(2%)	-12%
EBIT	155	(7%)	52	(3%)	-66%
Net Income	92	(4%)	11	(1%)	-88%
EPS	1.10		0.13		-88%
EPS pre <sup>1</sup>	1.14		0.32		-72%
EBITDA	250	(12%)	166	(8%)	-34%
thereof exceptionals	-4	(0%)	-21	(1%)	>100%
EBITDA pre exceptionals	254	(11.8%)	187	(9.1%)	-26%


- Sales decline mainly on lower prices (-11%) and negative currency (-4%); volumes mitigate (+9%)
- COGS decrease underproportionally to sales due to lower price levels mainly in Performance Polymers, risen D&A and inventory devaluation
- Overhead cost reduction reflects overall cost discipline
- Exceptional expenses from "Advance" reflected in earnings

Cost discipline and restructuring efforts start to become visible

2012 restated due to IAS 19 (revised)

Net of exceptionals, using the country tax rate applicable where the expenses were incurred

# Q3 2013: Advanced Intermediates and Performance Chemicals comparably resilient




Total group sales and EBITDA pre figures include reconciliation

<sup>1</sup> As of April 1st 2013 BU ION (Ion Exchange Resins) renamed to BU LPT (Liquid Purification Technologies)

<sup>2</sup> As of January 1st 2013 BU TRP (Technical Rubber Products) split into BU KEL (Keltan Elastomers) and BU HPE (High Performance Elastomers)

# Performance Polymers: Volumes recovering – prices remain at low levels



\* Net of capitalized borrowing costs and projects financed by customers

# Advanced Intermediates: Strong and stable agro business

[€ m]	Q3 2012	Q3 2013	Δ
Sales	403	403	0%
EBIT	58	51	-12.1%
Depr. / Amort.	17	20	17.6%
EBITDA pre exceptionals	75	71	-5.3%
Margin	18.6%	17.6%	
Capex*	22	28	27.3%

9M 2012	9M 2013	Δ	
1,231	1,229	-0.2%	
174	164	-5.7%	
50	56	12.0%	
224	216	-3.6%	
18.2%	17.6%		
54	70	29.6%	

#### Q3 comments

- Stable sales as positive volumes (both BUs with strong agro demand) offset negative price and currency effects
- BU All with good demand in flavor & fragrances
- Prices reflect lower raw material costs (e.g. benzene, toluene)
- Strong earnings and profitability on good utilization rates, however slightly burdened by headwinds from currency and some ramp-up costs for new cresol capacities
- Increased capex due to new dedicated projects in BU SGO



<sup>\*</sup> Net of capitalized borrowing costs, projects financed by customers and finance lease

13

LANXESS

# Performance Chemicals: Positive volumes and stable prices

€ m]	Q3 2012	Q3 2013	Δ	9M 2012	9M 2013	Δ			
Sales	555	546	-1.6%	1,698	1,627	-4.2%		-	
EBIT	54	51	-5.6%	156	86	-44.9%		3 1	
Depr. / Amort.	21	21	0%	65	70	7.7%	A STATE OF THE PARTY NAMED IN	1	
EBITDA pre exceptionals	75	72	-4%	236	190	-19.5%			
Margin	13.5%	13.2%		13.9%	11.7%				
Capex*	29	24	-17.2%	61	77	26.2%			
Q3 c	omments				Q3 sal	es bridç	je yoy	[€ m]	
Minor price movements acr			A		0%	3%	-5%	0%	
suffering from weak chrome	ore business	\$							
Headwind from currency eff		Ü		55	5				546
<ul> <li>Positive EBITDA developme (accelerators) and LPT (waw with stable performance</li> </ul>				03.20	012 Price	(approximate i		Portfolio :	02 2012
		_EA complete		Q3 21	UIA FIICE	voluille C	urreficy	r or dollo	W2 ZU 13

\* Net of capitalized borrowing costs, projects financed by customers and finance lease

**LANXESS** 

14

# Working capital reduction positively reflected in most KPIs

[€ m]	Dec 2012	Jun 2013	Sep 2013
Total assets/liabilities	7,519	7,268	7,111
Equity	2,330	2,198	2,147
Equity ratio	31%	30%	30%
Net financial debt	1,483	2,018	1,822
Net financial debt/EBITDA <sup>1</sup>	1.21	2.33	2.28
Near cash, cash & cash equivalents	797	371	518
Pension provisions	893	921	917
ROCE <sup>1</sup>	15.6%	8.4%	6.9%
Net working capital	1,849	2,082	1,873
Net working capital/sales <sup>1</sup>	20%	24%	22%
DSI (in days) <sup>2</sup>	65	64	61
DSO (in days) <sup>2</sup>	47	51	50

- Net financial debt reduced mainly due to working capital management
- Further net financial debt reduction targeted for year-end
- Net financial debt/EBITDA ratio improves slightly
- Cash positions increase accordingly with working capital reduction
- All working capital ratios improved sequentially

**LANXESS** 

# Q3 2013: Working capital management supports free cash flow

[€ m]	Q3 2012	Q3 2013
Profit before tax	119	20
Depreciation & amortization	95	114
Gain from sale of assets	0	0
Result from equity investments	3	0
Financial (gains) losses	23	29
Cash tax payments/refunds	-41	3
Changes in other assets and liabilities	50	38
Operating cash flow before changes in WC & CTA	249	204
Changes in working capital	95	174
CTA funding*	0	0
Operating cash flow	344	378
Investing cash flow	-185	-215
thereof capex**	-152	-146
Financing cash flow	-91	-62

- Profit before tax down due to weak operational performance
- D&A rises mainly as new plant for BTR (SG) now fully recognized in depreciation
- Tax refunds due to timing patterns and lower earnings
- Changes in working capital driven by cash inflow from reduced inventories
- Financing cash flow mirrors slight reduction of gross debt sequentially

CTA (Contractual Trust Arrangement) funding formerly shown in investing cash flow Het of capitalized borrowing cost and finance lease

Based on last twelve months for EBIT, EBITDA or sales
 Days of sales inventory/Days of sales outstanding calculated on quarterly sales
 2012 restated due to IAS 19 (revised)

# **Agenda**

- Executive overview Q3 2013
- Business and financial review Q3 2013
- Outlook/Guidance

**LANXESS** 

# **Expectation unchanged: No improvement in Q4 2013**

#### **Current macro view**

- Demand has started to slightly improve from tire industry with some customers restocking in Europe and Americas
- Market prices for synthetic rubbers remain at low levels
- European OEM/automotive business still subdued
- Agro demand continues to be strong
- Upward movements in raw material prices visible (e.g. butadiene); uncertainties of near-term development remain

#### LANXESS manoeuvres through a tough year 2013

- Efficiency program "Advance" initiated and in implementation
- FY 2013 EBITDA pre guidance range narrowed: €710-760 m




All references to EBITDA are pre exceptionals

**LANXESS** 

18

# LANXESS Energizing Chemistry



# Housekeeping items for consideration

#### Additional financial expectations

Capex 2013:

reduced to ~€600 m

D&A 2013:

~€420 - €440 m

Reconciliation 2013:

expected between €180-200 m

Annual tax rate:

- mid-term: ~22% - in 2013: mid-term guidance not meaningful due to low earnings; tax rate will be higher

Hedging 2013: Hedging 2014: ~55% at 1.25 -1.35 USD/EUR ~40% at 1.25 -1.35 USD/EUR

IAS 19 revised; impact in 2013:

- operational result: low single-digit € million amount

- financial result: low single-digit € million amount



LANXESS

# 9M 2013 financial overview: Weak environment and one-time burdens characterize 9M 2013


[€ m]	9M 2012	9M 2013	yoy in %
Sales	6,971	6,286	-9.8%
EBITDA pre except.	984	559	-43.2%
margin	14.1%	8.9%	
EPS	5.50	0.54	-90.2%
EPS pre <sup>1</sup>	5.74	1.07	-84.8%
Capex <sup>2</sup>	381	398	4.5%
[€ m]	31.12.2012	30.09.2013	Δ %
Net financial debt	1,483	1,822	22.9%
Net working capital	1,849	1,873	1.3%
Employees	17,177	17,502	1.9%


- Sales decline mainly due to lower prices; currency effects strain additionally
- EBITDA and margin burdened by weak market environment from tire and OEM, overall higher idle costs, ramp-up costs (~€20 m) and inventory devaluation (~€20 m)
- EPS also includes ~€60 m exceptional items (efficiency program "Advance")
- Net financial debt rises due to low earnings

2012 restated due to IAS 19 (revised)


¹ Net of exceptionals, using the country tax rate applicable where the expenses were incurred

² Net of capitalized borrowing costs, projects financed by customers and finance lease









Total group sales and EBITDA pre figures include reconciliation

<sup>1</sup> As of April 1st 2013 BU ION (Ion Exchange Resins) renamed to BU LPT (Liquid Purification Technologies)

<sup>2</sup> As of January 1st 2013 BU TRP (Technical Rubber Products) split into BU KEL (Keltan Elastomers) and BU HPE (High Performance Elastomers)

**LANXESS** 

# 9M 2013: Challenging times reflected in results

[€ m]	9M 2012		9M 2013		yoy in %	
Sales	6,971	(100%)	6,286	(100%)	-10%	
Cost of sales	-5,329	(76%)	-5,098	(81%)	-4%	
Selling	-564	(8%)	-575	(9%)	2%	
G&A	-236	(3%)	-230	(4%)	-3%	
R&D	-147	(2%)	-134	(2%)	-9%	
EBIT	682	(10%)	169	(3%)	-75%	
Net Income	458	(7%)	45	(1%)	-90%	
EPS	5.50		0.54		-90%	
EPS pre <sup>1</sup>	5.74		1.07		-85%	
EBITDA	958	(14%)	501	(8%)	-48%	
thereof exceptionals	-26	(0%)	-58	(1%)	>100%	
<b>EBITDA</b> pre exceptionals	984	(14.1%)	559	(8.9%)	-43%	

- Sales decline due to lower prices (-8%) and additional negative currency effects (-2%); volumes remain stable (0%)
- Lower price levels (mainly Performance Polymers) and higher idle costs lead to a drop in gross margin
- One-time costs of ~€30 m² also digested in 9M 2013
- Exceptional expenses (€64 m) from "Advance" program reflected in earnings

2012 restated due to IAS 19 (revised)

¹ Net of exceptionals and respective tax effects

26 ² Ramp-up BTR in Singapore (-€20 m) and KEL technology change in Geleen (-€10 m)

# 9M 2013: Weak business performance reflected in cash flow

[€ m]	9M 2012	9M 2013
Profit before tax	592	62
Depreciation & amortization	276	332
Gain from sale of assets	-1	-1
Result from equity investments	-3	0
Financial (gains) losses	71	82
Cash tax payments/refunds	-90	-38
Changes in other assets and liabilities	-82	-70
Operating cash flow before changes in WC & CTA	763	367
Changes in working capital	-339	-56
CTA funding*	0	0
Operating cash flow	424	311
Investing cash flow	17	-164
thereof capex**	-381	-398
Financing cash flow	-316	-161

- Profit before tax significantly down in line with weak EBITDA and increased D&A
- Changes in other assets and liabilities in 2013 related to variable compensation
- Increase in working capital notably lower in 2013 YTD due to active inventory management and lower raw material prices
- Investing cash flow mirrors inflow from near cash assets

2012 restated due to IAS 19 (revised)

**LANXESS** 


27

# **Balance sheet**


[€ m]	Dec'12	Jun'13	Sep'13		Dec'12	Jun'13	Sep'13
Non-current assets	3,747	3,820	3,752	Stockholders' equity	2,330	2,198	2,147
Intangible assets	390	388	372	Non-current liabilities	3,559	3,097	3,062
Property, plant & equipment	2,994	3,081	3,046	Pension & post empl. provis.	893	921	917
Equity investments	8	0	0	Other provisions	304	286	281
Other investments	18	14	14	Other financial liabilities	2,167	1,681	1,661
Other financial assets	8	7	11	Tax liabilities	35	35	36
Deferred taxes	211	213	199	Other liabilities	78	103	96
Other non-current assets	118	117	110	Deferred taxes	82	71	71
Current assets	3,772	3,448	3,359	Current liabilities	1,630	1,973	1,902
Inventories	1,527	1,527	1,388	Other provisions	440	366	367
Trade accounts receivable	1,117	1,212	1,136	Other financial liabilities	167	740	723
Other financial & current assets	331	338	317	Trade accounts payable	795	657	651
Near cash assets	411	97	150	Tax liabilities	45	27	24
Cash and cash equivalents	386	274	368	Other liabilities	183	183	137
Total assets	7,519	7,268	7,111	Total equity & liabilities	7,519	7,268	7,111


- Inventories decrease driven by both lower raw material costs and lower volumes
- €500 m bond due in April 2014 reclassified from non-current to current liabilities


<sup>\*</sup> CTA (Contractual Trust Arrangement) funding formerly shown in investing cash flow \*\* Net of capitalized borrowing costs, projects financed by customers and finance lease




#### A well managed and conservative maturity profile Long term financing secured Liquidity and maturity profile as per September 2013 Well balanced maturity profile Private Placements 2022 - 3.50% 2027 - 3.95% Diversified financing sources Bond 2014 750 7.75% Bond 2016 500 5.5% Private placements 250 Syndicated credit facility -250 Incl. EIB Development banks Bilateral bank facilities -750 -1000 Availability period of EIB¹ facility has been prolonged by -1250 one year -1500 2013 2015 2016 2017 2018 2019 >2019 2014 All financing without financial covenants ■ Financial liabilities ■ Cash & cash equivalents ■ Near cash assets ■ Undrawn long-term facilities 1 European Investment Bank; in case of utilization in 2014 final maturity of EIB financing in 2019 at latest; EIB facility currently undrawn **LANXESS**














# Overview exceptional items Q3 and YTD

[€ m]	Q3 :	2012	Q3 2	2013	9M 2	012	9M :	2013
	Excep.	Thereof D&A	Excep.	Thereof D&A	Excep.	Thereof D&A	Excep.	Thereof D&A
Performance Polymers	1	0	8	0	3	0	8	0
Advanced Intermediates	0	0	0	0	0	0	-4	0
Performance Chemicals	0	0	0	0	17	2	40	6
Reconciliation	3	0	13	0	8	0	20	0
Total	4	0	21	0	28	2	64	6

**LANXESS** 

# **Abbreviations**

	Performance Polymers		Performance Chemicals
BTR PBR KEL* HPE*	Butyl Rubber Performance Butadiene Rubbers Keltan Elastomers High Performance Elastomers High Performance Materials	• MPP • IPG • FCC • LEA • RCH • RUC • LPT**	Material Protection Products Inorganic Pigments Functional Chemicals Leather Rhein Chemie Rubber Chemicals Liquid Purification Technologies
	Advanced Intermediates		
AII SGO	Advanced Industrial Intermediates Saltigo		

\* As of January 1st 2013 BU TRP split into BU KEL (Keltan Elastomers) and BU HPE (High Performance Elastomers)
\*\* As of April 1st 2013 BU ION (Ion Exchange Resins) renamed to BU LPT

# **Upcoming events**

#### 2013/2014

 Deutsche B\u00f6rse Deutsches Eigenkapitalforum Morgan Stanley Annual Asia Pacific Summit Morgan Stanley Global Chemicals Conference DZ Bank Equity Conference HSBC Zurich Investors Conference 2013 Deutsche Bank German Corporate Conference BofA Merrill Lynch European Chemicals Conference Oddo Midcap Forum Commerzbank German Investment Seminar Kepler Cheuvreux German Corporate Conference

 FY results 2013 Nomura Global Chemical Industry Leaders Conference

 Bankhaus Lampe Deutschland-Konferenz Natixis German Corporate Conference

 Q1 results 2014 AGM 2014 Q2 results 2014 Q3 results 2014

November 13 November 14 November 14 November 18 November 28 December 2/3 December 2/3 January 9/10 January 13/14 January 21/22

March 20 March 27/28 April 3 April 10 May 8 May 22 August 6 November 6 Frankfurt Singapore Boston Frankfurt Zurich

Tokyo London Lyon New York Frankfurt

London Baden-Baden Paris

**LANXESS** 

#### **Contact details Investor Relations**

Oliver

Email

ΔGM

Head of Investor Relations



: +49-221 8885 9611 : +49-214 30 959 49611 : +49-175 30 49611 : Oliver.Stratmann@lanxess.com Fax. Mobile

Tel. : +49-221 8885 3851 Fax. : +49-221 8885 4944 Mobile : +49-175 30 23851 Email : Verena.Kehrenberg@lanxess.com

LANXESS IR website

Tanja Satzer Private Investors /



Tel. Fax. : +49-221 8885 3801 : +49-221 8885 4944 Mobile: +49-175 30 43801 Email: Tanja.Satzer@lanxess.com

Assistant

Investor Relations

Institutional Investors Analysts



Tel. : +49-221 8885 5458 Fax. : +49-221 8885 4944 Mobile : +49-175 30 50458 Email : Ulrike.Weihs@lanxess.com

Institutional Investors Analysts



Tel. : +49-221 8885 8007 Fax. : +49-221 8885 4944 Mobile : +49-175 30 58007 Email : Dirk.Winkels@lanxess.com

Institutional Investors Analysts



Tel. : +49-221 8885 2030 Fax. : +49-221 8885 4944 Mobile : +49-175 30 42030 Email : Joachim.Kunz@lanxess.com

